3月25日，在亚洲青年领袖论坛健康与医疗主题论坛上，第十四届全国人大代表，广药集团党委书记、董事长李楚源发表主旨演讲。
全文如下：
各位领导、各位专家、各位同仁：
大家好！很高兴再次与各位新老朋友相聚在美丽的花城广州，与各位一起共同探讨如何应对人类健康面临的新挑战，紧抓新机遇，推动新合作，携手共建人类卫生健康共同体。
当下，世界之变、时代之变、历史之变正以前所未有的方式展开，带来众多挑战。中国有句古话，叫做“日日行，不怕千万里；常常做，不怕千万事”。过去几十年，亚洲地区开放合作，锐意创新，创造了“亚洲奇迹”。在生物医药健康领域，亚洲已经成为除欧美之外的另一个国际生物医药产业中心区域。亚洲好，世界才能更好。我认为，在后疫情时代，亚洲打造生物医药与健康产业新高地，其时已至，其势已成，其兴可待。
一、亚洲生物医药健康产业迎来跨越发展新机遇
一是向阳而生，亚洲生物医药健康产业生机盎然。经过多年的发展，亚洲已经成为全球第二大生物医药产业中心区域。日本跻身生物技术强国之列，中国、印度、新加坡等亚洲国家逐渐成为全球生物医药创新发展的重要力量。近五年，我国在技术进步和消费能力提升的驱动之下，生物医药市场规模从2622亿元增加至4644亿元，2021年复合增长率达到20%。
二是疫后初霁，亚洲生物医药健康产业生逢其时。一方面，疫情让人们对健康愈加重视，随着亚洲人口老龄化程度不断提高，加之生物技术不断革新，将为产业发展创造新的历史机遇和内生动力。另一方面，数字经济的蓬勃发展，促进BT+IT融合，带动行业快速发展，2021年中国医药电商规模已突破2000亿元，预计未来十年市场规模年化增速将达22.6%。
三是驱动发展，亚洲生物医药健康产业生生不息。亚洲生物医药行业的高速发展促进了区域内经济的发展。中国生物医药行业产值约为300亿美元，每年增速约10%。印度生物医药行业产值约为110亿美元并以每年约20%的增速高速发展。新加坡已经成长为全球级别的生物医药中心，生物医药产业总值约为160亿美元，成为除电子业之外，新加坡最“吸金”的产业。
二、广州生物医药健康产业不断积聚发展新动能
去年，总书记在亚太经合组织工商领导人峰会上发表书面演讲，强调中国将坚定不移推动构建亚太命运共同体，共同守护人类生命健康。作为中国通向世界的南大门、粤港澳大湾区的核心城市、“一带一路”建设主动脉的重要节点，广州正大力打造生物医药健康产业高地，我认为可以成为亚洲生物医药健康产业高质量发展的重要引擎。
一是壮大生物医药新兴支柱产业，广州有基础。广州是国家生物产业基地，近年来，广州生物医药产业年均增长10%左右，现有各类生物医药企业6400多家，总数居全国第三，上市企业达47家，居全国第四，计划于2025年实现2100亿元的目标。
二是夯实生物医药健康产业创新基础，广州有底气。广州集聚了生物医药领域6家国家重点实验室、5名诺贝尔奖获得者、23位院士、229位国家重大人才工程入选者。近三年，广州累计获批国产药品3247件，新药临床批件149个，II、III类医疗器械1127件，数目创历史新高。
三是提升生物医药健康产业发展质效，广州有能力。2019年以来，广州连续出台多个推动生物医药产业发展的政策措施，广州生物医药健康产业初步形成规模化、集群化、融合化和生态化的发展优势和先导地位，总体水平跻身国家第一梯队。这些都让广州成为生物医药产业落地生根、开花结果的兴业乐土。
三、广药集团推动广州生物医药产业发展的新作为
得益于千年商都广州的“产业沃土”，近年来广药集团乘势而上，取得一系列成果：于2021年成为全球首家以中医药为主业的世界500强企业，目前位居第467位，在全球最具价值医药品牌榜单中名列第18位。集团旗下拥有白云山和康美药业两家上市公司，以及王老吉、陈李济等著名老字号品牌，目前全力打造世界一流医药健康综合性大集团。广药集团一直坚持与海内外深化合作,力促生物医药健康产业高质量发展。
一是以科技攻关为抓手，推动产学研创新要素集聚发展。近年亚洲生物制药已经逐步从单纯的制造转向研发。广药集团先后引进3名诺贝尔奖得主、21名国内院士及国医大师以及超百名博士及博士后，建成了7个国家级科研平台。去年，我们快速完成了治疗新冠轻症药物——白云山和黄透解祛瘟颗粒（即“肺炎1号方”）的产业化，还携手中山大学共建全国唯一的“生物医药与新型移动出行未来产业科技园”，布局未来产业。
二是以时尚中药为抓手，为世界健康提供“广药方案”。中国与亚洲诸国人文相亲，亚洲众多地区有使用汉方药的传统和习惯，早在上世纪初，王老吉就远销南洋各地，如今王老吉凉茶已出口至全球150个国家和地区。广药白云山华佗再造丸已连续十多年位居全国中成药出口第一名，并进入韩国、越南等多国医保。近年来，广药集团以时尚中药的健康养生理念，利用贵州刺梨等中国特色农产品，开发出大家座位上的“刺柠吉”高维C饮料时尚健康饮料，为大众健康提供不同的“广药方案”。当然，广药的大健康产品还包括荔小吉、灵芝孢子油等等。
三是以推动粤港澳大湾区医药产业融合发展为抓手，加速中医药国际化发展。粤港澳大湾区是“一带一路”建设的重要支撑，广药集团积极融入粤港澳大湾区建设，在澳门成立了国际总部，建设了广药国际澳门制药厂，并取得了澳门中药法实施以来首个中药制造准照、首个药品批文和首个中药制造GMP证书，为推动中医药现代化、国际化探索了新路径。
四是以建设中医药科普平台为抓手，向世界讲好中医药故事。中华文化源远流长，成为璀璨的亚洲文明的重要组成部分。广药集团一直以开放的姿态与世界对话，在美国纽约建成了首家海外王老吉博物馆，并启动了王老吉（东京）凉茶博物馆项目，计划在全球建立56个王老吉凉茶博物馆。我们在广州白云山麓建设的神农草堂中医药博物馆已经接待海内外游客280万人次，目前正对其进行扩建成为5A级的中医药博物馆。
亚洲国家谚语说，“遇山一起爬，遇沟一起跨”“甘蔗同穴生，香茅成丛长”。共赢合作是亚洲发展的必由之路。当前，我国上下正锚定高质量发展首要任务，推动经济实现质的有效提升和量的合理增长。广药集团将2023年发展主题定为“双效提升年”，坚持落实广州市“坚持产业第一，制造业立市”战略，助力生物医药健康产业高质量发展，包括拼科技，加强生物药、创新中药、仿创药的开发，为守护人类健康提供更多新药好药；拼市场，聚焦资源打造更多大品种，促进旗下12家中华老字号振兴发展，推动中医药产业化、现代化；拼国际化，深化澳门国际总部项目和横琴粤澳深度合作区产业基地等项目的建设，积极融入“双循环”新发展格局；拼数字化，积极发展数字经济，为医药健康企业的数字化转型探索新路径；防范化解重大风险，实现平安稳定有序发展。
“亲仁善邻、协和万邦”是中华文明一贯处世之道。本次论坛为亚洲各国青年才俊、精英对话交流提供了重要平台，在当前形势下恰逢其时，意义重大深远。站在生物产业迅猛发展的风口之上，亚洲生物医药健康产业迎来枝繁叶茂的蓬勃生长期。广药集团期待与亚洲各国、各科研机构、各企业加强合作，努力为提升人类健康水平，为亚洲经济高质量发展及人类命运共同体建设贡献广药力量。
Li Chuyuan says GPHL is dedicated to becoming a world-class comprehensive pharmaceutical corporation
On 25 March, Li Chuyuan, delegate to the 14th National People’s Congress of China and CPC committee secretary and chairperson of Guangzhou Pharmaceutical Holdings Limited, delivered a keynote speech at the Health and Medical Care Forum of the Asia Youth Leaders Forum. Following is the full text of the speech.
Excellencies,
Experts,
Colleagues,
Greetings! It is a great pleasure to meet again with friends old and new in the beautiful flower city of Guangzhou, to discuss with you how to deal with the new challenges facing global health, seize new opportunities, promote new cooperation, and work together to build a human community of health.
Right now, changes of the world, of our times, and of history are unfolding in ways like never before, which has given rise to many challenges. There is an old Chinese saying, “Keep walking and one will not be daunted by a thousand miles; make constant efforts and one will not be intimidated by a thousand tasks.” In the past few decades, the Asian region has been open and cooperative and dedicated to innovation, thus creating the “Asian miracle”. In the field of biopharma, Asia has become another international hub besides Europe and the United States. Only when Asia prospers can the world be even better. I believe that in the post-pandemic era, the time and conditions are ripe for Asia to become the new center of the biopharmaceutical industry.
Asia’s biopharma has been presented new opportunities for leapfrog development.
First, following the trend, Asia’s biopharma is full of vitality. After years of development, Asia has become the world’s second largest center of the biopharmaceutical industry. Japan is a considerable power in biotechnology, and China, India, and Singapore, among other Asian countries, are gradually becoming an important force in global biopharmaceutical innovation and development. In the past five years, driven by technological progress and the increase of buying power, the biopharmaceutical market has scaled from 262.2 billion yuan to 464.4 billion yuan, with a compound growth rate of 20% in 2021.
Second, past the pandemic, the time is just right for Asia’s biopharma. On the one hand, the pandemic has heightened people’s attention to health, and with increasing aging of Asia’s population and the continuous innovation of biotechnologies, it will create new historic opportunities and inner strength for the industry’s development. On the other hand, the booming development of the digital economy has promoted the integration of biotechnology and IT and driven the rapid development of the industry. China’s pharmaceutical e-commerce market exceeded 200 billion yuan in 2021, and the next decade is expected to see the market's annual growth rate reach 22.6%.
Third, with its driving force, Asia’s biopharma is ever-growing. The rapid development of the biopharmaceutical industry in Asia has boosted economic development of the region. The output of China’s biopharma is around 30 billion US dollars, with an annual growth rate of about 10%. India’s biopharma produces about 11 billion US dollars and is growing at a rapid rate of about 20% per year. Singapore has grown into a global biopharmaceutical center, with an industry worth of about 16 billion US dollars, making it the most money-making industry in Singapore besides electronics.
Guangzhou’s biopharma continues to accumulate new momentum for development.
Last year, President Xi Jinping delivered a written speech at the APEC CEO Summit, stressing that China will unswervingly promote the building of an Asia-Pacific community with a shared future and jointly safeguard people’s lives and health. As China’s southern gateway to the world, the core city of the Guangdong-Hong Kong-Macao Greater Bay Area, and an important part on the “Belt and Road”, Guangzhou is vigorously developing into a biopharmaceutical hub, which I believe can become an important engine for the high-quality development of Asia’s biopharma.
First, Guangzhou has the foundation to strengthen emerging pillar sectors in biopharma. Guangzhou is a national bio-industry base. In recent years, Guangzhou’s biopharma has grown by an average of about 10% per year. Now there are more than 6,400 biopharmaceutical companies of various types, ranking third in the country, and 47 listed companies, ranking fourth in the country. The industry is expected to reach the target of 210 billion yuan in 2025.
Second, Guangzhou has the confidence to achieve innovations in the biopharma. In the biopharmaceutical field, Guangzhou hosts 6 key national laboratories, 5 Nobel laureates, 23 academicians, and 229 national major talent project title-holders. In the past three years, Guangzhou has been approved a total of 3,247 domestic drugs, 149 clinical trials of new drugs, and 1,127 Class II and III medical devices, a record high.
Third, Guangzhou has the ability to improve the development quality of the biopharma. Since 2019, Guangzhou has successively introduced a number of policies and measures to promote the development of its biopharma. Now, Guangzhou’s biopharma has basically grown into an industry of scale, clusters, integration, ecosystems, and a leading position. It ranks among the first tier in the whole country. All these have made Guangzhou a fertile land for the biopharmaceutical industry to take root and blossom.
GPHL’s new endeavors promotes the development of Guangzhou’s biopharma.
Thanks to this “fertile land” of Guangzhou, the Millennium Business Capital, we have seized the opportunities in recent years and achieved a series of results. In 2021, we became the world’s first Fortune 500 companies whose main business is TCM, and currently stands at the 467th. We have also ranked the 18th in the World’s Most Valuable Pharmaceutical Brands. We own two listed companies, Baiyunshan Pharmaceutical and Kangmei Pharmaceutical, as well as well-known time-honored brands such as Wanglaoji and Chenliji. We are dedicated to becoming a world-class comprehensive pharmaceutical group, and we have been deepening cooperation in and out of China to promote the high-quality development of the biopharmaceutical industry.
First, we utilize scientific and technological research to promote the clustering of industry-university-research innovation factors. In recent years, biopharmaceutical practices in Asia have gradually shifted from pure manufacturing to R&D. We have successively brought in 3 Nobel laureates, 21 domestic academicians and TCM masters, and more than 100 doctoral and postdoctoral researchers. We have also developed 7 national scientific research platform. Last year, we achieved fast large-scale production of a drug for slight COVID symptoms: HBYS Toujie Quwen Granule (aka COVID Prescription #1). In addition, we joined hands with Sun Yat-sen University to build the nation’s only future industries science and technology park for biopharma and new mobility, as a bid for future industries.
Second, we utilize “relevant TCM” to supply GPHL solutions to global health. China shares similar cultures with its Asian peers. Many regions in Asia have the tradition and habit of using TCM. As early as the beginning of the last century, Wanglaoji was sold to all parts of Southeast Asia. Nowadays, this herbal tea has been exported to 150 countries and regions around the world. Huatuo Zaizao Pill has been the largest export of Chinese patent medicine for more than a decade and has been included in the medical insurance of South Korea, Vietnam, etc. In recent years, under this health philosophy of relevant TCM, we have turned distinctive Chinese agro-products like prickly pears into Ci Ning Ji, right beside your seat. It’s a modern beverage with high Vitamin C, a new GPHL solution to public health. Our “big health” products also include Lixiaoji and Lingzhi Baozi Oil Capsule.
Third, we utilize the promotion of integrated medical development in the Greater Bay Area to advance TCM’s development in the global market. The Greater Bay Area is an important support for the implementation of the Belt and Road Initiative, and we actively contribute to the development of this area. We have established our international headquarters in Macao; built the GPHL International (Macao) Pharmaceutical Factory; and obtained the first TCM manufacturing license, the first drug approval, and the first GMP certificate for TCM manufacturing since the implementation of Macao’s TCM Law. These have blazed new trails for TCM’s modernization and global recognition.
Fourth, we utilize the development of a platform for popular TCM sciences to share with the world the story of TCM. Chinese culture has a long history and is an integral part of the diverse Asian civilization. We have always been in dialogue with the world with an open attitude. We have built the first overseas Wanglaoji Museum in New York, USA, and launched the Wanglaoji (Tokyo) Herbal Tea Museum project. We plan to establish 56 such museums around the world. At the hills of the Baiyun Mountain, our Guangzhou Shennong Traditional Chinese Medicine Museum has received 2.8 million visitors from home and abroad. Currently we are expanding it into a 5A-rated TCM museum.
There are these sayings in Asia. “Climb mountains and cross ditches ahead together.” “Sugarcane and lemongrass grow in dense clumps.” Win-win cooperation is the way forward for Asia’s development. At present, the whole of China is striving for the primary goal of high-quality development and promoting the economy’s effective improvement in quality and reasonable increase in quantity. We have defined the development theme for 2023 to be the “Year of Efficiency and Effectiveness Improvement”. We will implement Guangzhou’s strategy of “industries first with special focus on manufacturing” and contribute to the high-quality development of the biopharmaceutical industry. We will strengthen scientific research, including the R&D of biological drugs, innovative TCM drugs, and me-too drugs, to provide more new and good drugs for people’s health. We will further develop the market, concentrating resources to create more varieties and revitalize the development of our 12 time-honored brands, so as to upscale and modernize the TCM industry. We will go global, through the development of our international headquarters in Macao and the industry base in the Guangdong-Macao In-Depth Cooperation Zone in Hengqin and synergy with the new “dual circulation” development paradigm. We will pursue digitalization, including active development of the digital economy, to explore new paths for the digital transformation of pharmaceutical companies. We will also prevent and resolve major risks to achieve safe, stable development in an orderly fashion.
Seeking goodwill with neighbors and harmony with all nations is the Chinese way of engaging with the world. This forum provides young talents and elites from across Asia with an important platform for dialogue and idea exchange. Under current circumstances, it is both relevant and significant. Riding the wave of the rapid development of the bio-industry, Asia’s biopharma is looking at a flourishing period for growth. GPHL looks forward to working more closely with countries, scientific research institutions, and companies from Asia to contribute our efforts to the improvement of global health, high-quality development of the Asian economy, and the building of a community with a shared future for humanity.
|
欢迎来到亚洲青年领袖论坛官网